テルイ ヤスヒト
TERUI Yasuhito
照井 康仁 所属 埼玉医科大学 医学部 血液内科 職種 教授 |
|
論文種別 | 学術雑誌(原著) |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia |
掲載誌名 | 正式名:Cancer Sci ISSNコード:13497006 |
掲載区分 | 国外 |
巻・号・頁 | 111,3327-3337頁 |
著者・共著者 | Sekiguchi, N., Rai, S., Munakata, W., Suzuki, K., Handa, H., Shibayama, H., Endo, T., Terui, Y., Iwaki, N., Fukuhara, N., Tatetsu, H., Iida, S., Ishikawa, T., Shiibashi, R., Izutsu, K. |
発行年月 | 2020 |
概要 | Tirabrutinib is a second-generation Bruton's tyrosine kinase inhibitor with greater selectivity than ibrutinib. Here, we conducted a multicenter, phase II study of tirabrutinib in patients with treatment-naïve (Cohort A) or with relapsed/refractory (Cohort B) Waldenström's macroglobulinemia (WM). Patients were treated with tirabrutinib 480 mg once daily. The primary endpoint was major response rate (MRR; ≥ partial response). Secondary endpoints included overall response rate (ORR; ≥ minor response), time to major response (TTMR), progression-free survival (PFS), overall survival (OS), and safety. In total, 27 patients (18 in Cohort A; 9 in Cohort B) were enrolled. The median age was 71 y, and the median serum immunoglobulin M level was 3600 mg/dL. Among the patients, 96.2% had the MYD88 |
DOI | 10.1111/cas.14561 |
文献番号 | 32639651 |